AIMD

Ainos, Inc. operates as a diversified company focused on artificial intelligence solutions and biohealth technologies. Headquartered in Tokyo, Japan, the company develops and commercializes AI-driven platforms for healthcare applications, including diagnostic support systems and drug discovery tools. Ainos maintains operations through its subsidiaries, including entities focused on regenerative medicine research and AI-based medical data analysis. The company's business model centers on licensing its proprietary AI technologies to healthcare providers, pharmaceutical companies, and research institutions, while also pursuing development of its own therapeutic candidates. Ainos has established partnerships with medical institutions in Japan and internationally to validate and deploy its AI diagnostic platforms. In recent years, the company has expanded its focus beyond traditional biotech into broader AI applications, seeking to leverage machine learning capabilities across multiple sectors. The firm operates research facilities in Japan and maintains a relatively small workforce typical of early-stage technology companies. Ainos trades on the NASDAQ Capital Market under the ticker symbol AIMD following its U.S. listing. The company continues to invest in clinical validation studies for its healthcare AI platforms while exploring additional revenue streams through technology licensing agreements. As a development-stage enterprise, Ainos allocates significant resources to research and development activities aimed at advancing its AI and biohealth product pipeline.